221077-49-2

Upstream product

• 221077-42-5 tert-butyl (1S)-1-(4-hydroxy-3-iodobenzyl)-2-oxo-2-(pentylamino)ethylcarbamate 
• 557-21-1 dicyanozinc 

Downstream Products

• 221077-52-7 methyl 2-[4-[(2S)-2-({(2S)-2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoyl}amino)-3-oxo-3-(pentylamino)propyl]-2-(1(2H)-tetrazol-5-yl)phenoxy]acetate 
• 221077-51-6 methyl 2-{4-[(2S)-2-({(2S)-2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoyl}amino)-3-oxo-3-(pentylamino)propyl]-2-cyanophenoxy}acetate 
• 221077-50-5 methyl 2-{4-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-oxo-3-(pentylamino)propyl]-2-cyanophenoxy}acetate 

Relevant academic research and scientific papers

Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: Identification of a tetrazole-containing inhibitor with cellular activity

Protein tyrosine phosphatases (PTPs) constitute a diverse family of enzymes that, together with protein tyrosine kinases, control the level of intracellular tyrosine phosphorylation, thus regulating many cellular functions. PTP1B negatively regulates insu

Inhibitors of protein tyrosine phosphatase

The present invention comprises small molecular weight, non-peptidic inhibitors of formula I and II of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM).